title: Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.
abstract: The paclitaxel/cisplatin combination therapy commonly is used as the first-line treatment for advanced ovarian cancer patients. Midkine (MK), known as a novel tumor biomarker, has been elevated in the serum of patients with epithelial ovarian cancer (EOC). In this study, we aimed to detect the expression of MK in EOC tissues and evaluate clinical value of MK in diagnosis and therapy of EOC. We perform immunohistochemistry analysis to detect MK in EOC sample with postoperative platinum/paclitaxel combination therapy, we found that 71.4% (85 in 119 samples) of these samples were MK positive (> 10% of the cells were stained), and the expression of MK was significantly associated with disease histology (P = 0.038) as well as differentiation grade (P < 0.001). Moreover, MK positive samples show much more sensitive to cisplatin/paclitaxel combination therapy, compared with MK negative samples (P = 0.029). Those results indicated that MK expression might correlate with paclitaxel and/or cisplatin cytotoxicity in clinical therapy of EOC. Then, we evaluated the sensitivity to cisplatin and paclitaxel in 5 ovarian cancer cell lines (ES2, A2870, HO-8910, SKOV3 and SW626), and ES2, the highest MK expression among those cell lines, show the most sensitive to paclitaxel and cisplatin. Further, we confirmed this correlation between MK and paclitaxel and/or cisplatin cytotoxicity with the gain- and lost- of function. Finally, we demonstrated that MK enhanced the cytotoxicity of paclitaxel and/or cisplatin by accumulated cisplatin and paclitaxel through inhibited the expression of multidrug resistance-associated protein 3 (MRP3). In conclusion, MK could be an effective biomarker in diagnosis and therapy of EOC, especially for the drug selection at the time of initial diagnosis.
authors.affiliation: Nanjing First Hospital, Nanjing Medical University Nanjing, China.
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Wu
authors.affiliation: Nanjing First Hospital, Nanjing Medical University Nanjing, China.
authors.forename: Xiaogai
authors.initials: X
authors.lastname: Zhi
authors.affiliation: Jiangsu Cancer Hospital Nanjing, China.
authors.forename: Minghua
authors.initials: M
authors.lastname: Ji
authors.affiliation: Department of Pathology, Xuzhou Medical College Xuzhou, China.
authors.forename: Qingling
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Nanjing First Hospital, Nanjing Medical University Nanjing, China.
authors.forename: Yujuan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Nanjing First Hospital, Nanjing Medical University Nanjing, China.
authors.forename: Jingyan
authors.initials: J
authors.lastname: Xie
authors.affiliation: Nanjing First Hospital, Nanjing Medical University Nanjing, China ; State Key Laboratory of Reproductive Medicine, Nanjing Medical University Nanjing, China.
authors.forename: Shuli
authors.initials: S
authors.lastname: Zhao
keywords: Epithelial ovarian cancer (EOC); cisplatin/paclitaxel combination therapy; drug sensitivity; immunostaining; midkine